DMAC
DiaMedica Therapeutics Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
DiaMedica Therapeutics Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of DiaMedica Therapeutics Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of DiaMedica Therapeutics Inc.'s 6 closest co-movers, none share that code.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+3.31%
vs ±15.9% implied · ×0.21
shaded = implied · ▲▼ = realized
No other changes.
No other changes.
Annual filing, covered
10-K parsed · Mar 30 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 30 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
No trades yet today.
No trades yet today.
Expected move
No implied move.
Largest filed tie
—
DiaMedica Therapeutics Inc.
9.96
pre 10.45 +4.50%
| Manager | Value | % base | |
|---|---|---|---|
| Cooperman Leon G | $24.3M | 27.70% | +70.79% |
| BlackRockindex-like | $15.9M | 18.08% | +21.34% |
| Geodeindex-like | $6.3M | 7.18% | +14.55% |
| Millennium | $6.0M | 6.79% | −9.65% |
| State Streetindex-like | $4.6M | 5.19% | +0.39% |
| Manager | Value | % base | |
|---|---|---|---|
| Cooperman Leon G | $24.3M | 27.70% | +70.79% |
| BlackRockindex-like | $15.9M | 18.08% | +21.34% |
| Geodeindex-like | $6.3M | 7.18% | +14.55% |
| Millennium | $6.0M | 6.79% | −9.65% |
| State Streetindex-like | $4.6M | 5.19% | +0.39% |
Bull2
Bear1